<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02812524</url>
  </required_header>
  <id_info>
    <org_study_id>16-042</org_study_id>
    <nct_id>NCT02812524</nct_id>
  </id_info>
  <brief_title>Ipilimumab for Head and Neck Cancer Patients</brief_title>
  <official_title>Intratumoral Ipilimumab in Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Providence Health &amp; Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Providence Health &amp; Services</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for patients with squamous cell carcinoma of the head and neck (SCCHN). This&#xD;
      study will test the feasibility of the administration of intratumoral injections of&#xD;
      ipilimumab prior to surgical resection, and the immune system response to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test intratumor microdosing of ipilimumab (antagonistic antibody directed to&#xD;
      Cytotoxic T-Lmphocyte-Associated Protein 4 [CTLA-4]) 7-10 days prior to planned surgical&#xD;
      resection of tumor and involved lymph nodes in patients with SCCHN. Tissue, peripheral blood,&#xD;
      saliva and stool samples will be obtained for immunologic end points. The primary objective&#xD;
      is to assess safety, as determined by the number of surgeries that are delayed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 18, 2016</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgery delay</measure>
    <time_frame>7-10 Days</time_frame>
    <description>The percentage of patients with surgery delayed possibly related to the study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of paired tissue sample acquisition</measure>
    <time_frame>7-10 Days</time_frame>
    <description>The number of tissue samples that can be collected which were: biopsied, injected, and resected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptance of study</measure>
    <time_frame>28 Days</time_frame>
    <description>The screening-to-enrollment ratio will be calculated.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Failure rate of planned laboratory assays</measure>
    <time_frame>7-10 days</time_frame>
    <description>The percentage of assays achieving a result.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Intratumoral Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a 3mg intratumoral injection of ipilimumab during a biopsy procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intratumoral Ipilimumab</intervention_name>
    <description>Patients with a planned resection of SCCHN will have a biopsy procedure 7-10 days prior to surgery and receive an injection of ipilimumab directly into a tumor.</description>
    <arm_group_label>Intratumoral Ipilimumab</arm_group_label>
    <other_name>Yervoy</other_name>
    <other_name>BMS734016</other_name>
    <other_name>MDX-010</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with SCCHN who are planned for surgical resection and in the opinion of the&#xD;
             surgeon are able to safely undergo tissue biopsy plus intratumoral (IT) injection in&#xD;
             advance, with special consideration given to risk of occlusion or compression of&#xD;
             airway or major vessels in the neck, secondary to tumor swelling, or erosion into a&#xD;
             major vessel in the case of necrosis.&#xD;
&#xD;
          -  Age 18 years or above with ability to give informed consent, comply with the protocol&#xD;
             and sign a study-specific consent document. Patients with history of psychiatric&#xD;
             illness must be judged by the investigator as able to understand the investigational&#xD;
             nature and risks associated with the therapy.&#xD;
&#xD;
          -  Any Eastern Cooperative Oncology Group (ECOG) performance status deemed suitable by&#xD;
             investigator for requirements of study, to potentially include incisional office&#xD;
             biopsy of lesion, or image guided multiple 18g core needle biopsies (5 minimum) by&#xD;
             interventional radiology, followed immediately by direct injection of lesion with&#xD;
             drug.&#xD;
&#xD;
          -  Patients must have blood test results within protocol-specified parameters&#xD;
&#xD;
          -  Men must agree to not attempt to become a new father for a total of 165 days&#xD;
             post-treatment completion&#xD;
&#xD;
          -  Women must agree not to become pregnant for a total of 105 days post treatment&#xD;
             completion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinical factors such as bleeding, active infection, colitis history or&#xD;
             psychiatric factors that in the judgment of the investigator would preclude safe&#xD;
             participation and compliance with study procedures.&#xD;
&#xD;
          -  Need for chronic maintenance oral steroids â‰¥ 20mg prednisone daily equivalent; inhaled&#xD;
             steroids are acceptable.&#xD;
&#xD;
          -  History of or current active autoimmune diseases, [e.g. including but not limited to&#xD;
             inflammatory bowel diseases (IBD), rheumatoid arthritis, autoimmune thyroiditis,&#xD;
             autoimmune hepatitis, systemic sclerosis (scleroderma and variants), systemic lupus&#xD;
             erythematosus, autoimmune vasculitis, autoimmune neuropathies (such as Guillain-Barre&#xD;
             syndrome), which in the judgment of the investigator pose an active and significant&#xD;
             risk. Vitiligo and adequately controlled endocrine deficiencies such as hypothyroidism&#xD;
             are not exclusionary.]&#xD;
&#xD;
          -  Infectious diseases including human immunodeficiency virus (HIV), Hepatitis B virus&#xD;
             (HBV) and hepatitis C virus (HCV).&#xD;
&#xD;
          -  Patients who have had a history of acute diverticulitis, intra-abdominal abscess, GI&#xD;
             obstruction and abdominal carcinomatosis which are known risk factors for bowel&#xD;
             perforation, and in the judgment of the investigator still pose an active risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rom S Leidner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Health &amp; Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. Bryan Bell, MD, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Health &amp; Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rom S. Leidner, MD</last_name>
    <phone>503-215-5696</phone>
    <email>Rom.Leidner@Providence.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>R. Bryan Bell, MD, DDS</last_name>
    <phone>(503) 215-3053</phone>
    <email>Richard.Bell@Providence.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Portland Providence Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Fisher, RN</last_name>
      <phone>503-215-2613</phone>
      <email>Brenda.Fisher@providence.org</email>
    </contact>
    <investigator>
      <last_name>Brendan Curti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Crocenzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel Sanborn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Walter J. Urba, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alison Conlin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Godwin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rom Leidner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rui Li, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard B. Bell, MD, DDS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Page, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://oregon.providence.org/our-services/p/providence-cancer-center/</url>
    <description>Providence Cancer Center</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2016</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Yervoy</keyword>
  <keyword>Head and neck cancer</keyword>
  <keyword>Pre-operative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

